ClinicalTrials.gg
CompletedNCT01575834FRAMEUpdated Aug 28, 2024Results posted

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

A Phase 3 interventional study of Romosozumab and Placebo in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 218 sites in 24 countries. Open to female participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,180
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing romosozumab in Osteoporosis, Postmenopausal — 1 open to participants now, 2 under way, none of them phase 3. romosozumab · Osteoporosis, Postmenopausal.

Enrollment
Largest of 12
7,180 · median 268
Started
2012
with 2 others
Phase 3
6 of 12
none open now
Registered
2nd of 12
by date
Lead sponsor
9 of 12
Amgen

Among the 12 studies testing romosozumab in Osteoporosis, Postmenopausal, this one has the largest enrollment, is one of 3 that started in 2012, is one of 6 in phase 3, and was the 2nd registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 12 studies testing romosozumab in Osteoporosis, Postmenopausal is open now. Recruiting first, the newest first:

About romosozumab

romosozumab: first FDA approval 2019 (EVENITY), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing romosozumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with osteoporosis, defined as low bone mineral density (BMD T-score at the total hip or femoral neck of ≤ -2.50)

Exclusion criteria

Exclusion Criteria:

  • BMD T-score of ≤ -3.50 at the total hip or femoral neck
  • History of hip fracture
  • Any severe or more than 2 moderate vertebral fractures, as assessed by the central imaging based on lateral spine x-rays
  • Use of agents affecting bone metabolism
  • History of metabolic or bone disease (except osteoporosis)
  • Vitamin D insufficiency (vitamin D repletion and rescreening is permitted)
  • Current hyper- or hypocalcemia
  • Current, uncontrolled hyper- or hypothyroidism
  • Current, uncontrolled hyper- or hypoparathyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7,180 participants (actual)

Study arms

  • Experimental
    Romosozumab

    Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.

    Drug: Romosozumab · Drug: Denosumab

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.

    Drug: Placebo · Drug: Denosumab

Interventions

  • Administered by subcutaneous injection once a month (QM)

    Also known as: AMG 785, EVENITY™

  • DrugPlacebo

    Administered by subcutaneous injection once a month (QM)

  • Administered by subcutaneous injection once every 6 months (Q6M)

    Also known as: Prolia®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With New Vertebral Fracture Through Month 12

    New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method. The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.

    Time frame: 12 Months

  2. Percentage of Participants With New Vertebral Fracture Through Month 24

    New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method. The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.

    Time frame: 24 months

Secondary outcomes

  1. Percentage of Participants With a Clinical Fracture Through Month 12

    Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 12 Months

  2. Percentage of Participants With a Nonvertebral Fracture Through Month 12

    A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 12 Months

  3. Percentage of Participants With a Nonvertebral Fracture Through Month 24

    A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 24 Months

  4. Percentage of Participants With a Clinical Fracture Through Month 24

    Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 24 Months

  5. Percentage of Participants With a Major Nonvertebral Fracture Through Month 12

    A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.

    Time frame: 12 Months

  6. Percentage of Participants With a Major Nonvertebral Fracture Through Month 24

    A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.

    Time frame: 24 Months

  7. Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12

    A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.

    Time frame: 12 Months

  8. Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24

    A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.

    Time frame: 24 Months

  9. Percentage of Participants With a Hip Fracture Through Month 12

    Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

    Time frame: 12 Months

  10. Percentage of Participants With a Hip Fracture Through Month 24

    Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

    Time frame: 24 Months

  11. Percentage of Participants With a Major Osteoporotic Fracture Through Month 12

    Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 12 Months

  12. Percentage of Participants With a Major Osteoporotic Fracture Through Month 24

    Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.

    Time frame: 24 Months

  13. Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12

    A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.

    Time frame: 12 Months

  14. Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24

    A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.

    Time frame: 24 Months

  15. Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and Month 12

  16. Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and Month 24

  17. Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and Month 12

  18. Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and Month 24

  19. Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and Month 12

  20. Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24

    Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

    Time frame: Baseline and Month 24

07

Results

Posted Nov 8, 2018

Participant flow

This study was conducted at 222 centers in Europe, Central/Latin America, Asia, North America, and Australia/New Zealand. The first participant enrolled on 15 March 2012 and the last participant enrolled on 06 December 2013.

Participant flow — Overall Study
MilestonePlacebo/DenosumabRomosozumab/Denosumab
Started35913589
Received double-blind treatment35823575
Completed double-blind period32053185
Completed 24-month study period30322994
Completed28922851
Not completed699738
Withdrew: Withdrawal by subject352390
Withdrew: Death8174
Withdrew: Other7070
Withdrew: Adverse event6361
Withdrew: Lost to follow-up5568
Withdrew: Noncompliance5227
Withdrew: Administrative decision1533
Withdrew: Ineligibility determined58
Withdrew: Protocol deviation43
Withdrew: Requirement for alternative therapy24

Outcome measures

PrimaryPercentage of Participants With New Vertebral Fracture Through Month 12

New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method. The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants With New Vertebral Fracture Through Month 12
percentage of participantsPlaceboRomosozumab
Percentage of Participants With New Vertebral Fracture Through Month 121.80.5
Statistical analysis
  • Placebo vs Romosozumab · Regression, Logistic · p = < 0.001 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Odds ratio (or): 0.27 · 95% CI 0.15 to 0.47Values \< 1 for odds ratio favor romosozumab.
PrimaryPercentage of Participants With New Vertebral Fracture Through Month 24

New vertebral fractures occurred when there was ≥ 1 grade increase from the previous grade of 0 in any vertebra from T4 to L4 using the Genant semiquantitative scoring method. The Genant semiquantitative scoring method was based on assessment of x-rays according to the following scale: * Grade 0 (Normal) = no fracture; * Grade 1 (Mild) = mild fracture, 20 to 25% reduction in vertebral height (anterior, middle, or posterior); * Grade 2 (Moderate) = moderate fracture, 25 to 40% reduction in anterior, middle, and/or posterior height; * Grade 3 (Severe) = severe fracture, greater than 40% reduction in anterior, middle, and/or posterior height.

Time frame:
24 months
Reported as:
Number · percentage of participants
Percentage of Participants With New Vertebral Fracture Through Month 24
percentage of participantsPlacebo/DenosumabRomosozumab/Denosumab
Percentage of Participants With New Vertebral Fracture Through Month 242.50.6
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · Regression, Logistic · p = < 0.001 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Odds ratio (or): 0.24 · 95% CI 0.15 to 0.39Values \< 1 for odds ratio favor romosozumab.
SecondaryPercentage of Participants With a Clinical Fracture Through Month 12

Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Fracture Through Month 12
percentage of participantsPlaceboRomosozumab
Percentage of Participants With a Clinical Fracture Through Month 122.51.6
Statistical analysis
  • Placebo vs Romosozumab · Cox proportional hazards · p = 0.008 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Hazard ratio (hr): 0.64 · 95% CI 0.46 to 0.89Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With a Nonvertebral Fracture Through Month 12

A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Nonvertebral Fracture Through Month 12
percentage of participantsPlaceboRomosozumab
Percentage of Participants With a Nonvertebral Fracture Through Month 122.11.6
Statistical analysis
  • Placebo vs Romosozumab · Cox proportional hazards · p = 0.096 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Hazard ratio (hr): 0.75 · 95% CI 0.53 to 1.05Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With a Nonvertebral Fracture Through Month 24

A nonvertebral fracture was defined as a fracture present on a copy of radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging confirming the fracture within 14 days of reported fracture image date as recorded by the study site, and/or documented in a copy of the radiology report, surgical report, or discharge summary, excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges. In addition, fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Nonvertebral Fracture Through Month 24
percentage of participantsPlacebo/DenosumabRomosozumab/Denosumab
Percentage of Participants With a Nonvertebral Fracture Through Month 243.62.7
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · Cox proportional hazards · p = 0.057 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Hazard ratio (hr): 0.75 · 95% CI 0.57 to 0.97Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With a Clinical Fracture Through Month 24

Clinical fractures included clinical vertebral and nonvertebral fractures (excluding skull, facial, mandible, cervical vertebrae, thoracic vertebrae, lumbar vertebrae, metacarpus, finger phalanges, and toe phalanges) that were associated with signs and/or symptoms indicative of a fracture. Clinical vertebral fractures were included regardless of trauma severity or pathologic fractures; nonvertebral fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Fracture Through Month 24
percentage of participantsPlacebo/DenosumabRomosozumab/Denosumab
Percentage of Participants With a Clinical Fracture Through Month 244.12.8
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · Cox proportional hazards · p = 0.096 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Hazard ratio (hr): 0.67 · 95% CI 0.52 to 0.87Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With a Major Nonvertebral Fracture Through Month 12

A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Major Nonvertebral Fracture Through Month 12
percentage of participantsPlaceboRomosozumab
Percentage of Participants With a Major Nonvertebral Fracture Through Month 121.51.0
Statistical analysis
  • Placebo vs Romosozumab · Cox proportional hazards · p = 0.096 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Hazard ratio (hr): 0.67 · 95% CI 0.44 to 1.02Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With a Major Nonvertebral Fracture Through Month 24

A major nonvertebral fracture was a subset of nonvertebral fractures including pelvis, distal femur (ie, femur excluding hip), proximal tibia (ie, tibia excluding ankle), ribs, proximal humerus (ie, humerus excluding elbow), forearm, and hip.

Time frame:
24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Major Nonvertebral Fracture Through Month 24
percentage of participantsPlacebo/DenosumabRomosozumab/Denosumab
Percentage of Participants With a Major Nonvertebral Fracture Through Month 242.81.9
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · Cox proportional hazards · p = 0.096 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Hazard ratio (hr): 0.67 · 95% CI 0.49 to 0.91Hazard ratio \< 1 favors romosozumab
SecondaryPercentage of Participants With a New or Worsening Vertebral Fracture Through Month 12

A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 12
percentage of participantsPlaceboRomosozumab
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 121.80.5
Statistical analysis
  • Placebo vs Romosozumab · Regression, Logistic · p = 0.096 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Odds ratio (or): 0.28 · 95% CI 0.17 to 0.49Values \< 1 for odds ratio favor romosozumab.
SecondaryPercentage of Participants With a New or Worsening Vertebral Fracture Through Month 24

A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4.

Time frame:
24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 24
percentage of participantsPlacebo/DenosumabRomosozumab/Denosumab
Percentage of Participants With a New or Worsening Vertebral Fracture Through Month 242.50.7
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · Regression, Logistic · p = 0.096 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Odds ratio (or): 0.26 · 95% CI 0.16 to 0.41Values \< 1 for odds ratio favor romosozumab.
SecondaryPercentage of Participants With a Hip Fracture Through Month 12

Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Hip Fracture Through Month 12
percentage of participantsPlaceboRomosozumab
Percentage of Participants With a Hip Fracture Through Month 120.40.2
Statistical analysis
  • Placebo vs Romosozumab · Cox proportional hazards · p = 0.18 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Hazard ratio (hr): 0.54 · 95% CI 0.22 to 1.35Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With a Hip Fracture Through Month 24

Hip fractures were defined as a subset of nonvertebral fractures including fractures of the femur neck, femur intertrochanter, and femur subtrochanter.

Time frame:
24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Hip Fracture Through Month 24
percentage of participantsPlacebo/DenosumabRomosozumab/Denosumab
Percentage of Participants With a Hip Fracture Through Month 240.60.3
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · Cox proportional hazards · p = 0.12 (A fixed-sequence testing procedure was used for multiplicity adjustment of the coprimary and a subset of secondary efficacy endpoints to maintain the overall significance level at 0.05.) · Hazard ratio (hr): 0.50 · 95% CI 0.24 to 1.04Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With a Major Osteoporotic Fracture Through Month 12

Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Major Osteoporotic Fracture Through Month 12
percentage of participantsPlaceboRomosozumab
Percentage of Participants With a Major Osteoporotic Fracture Through Month 121.81.1
Statistical analysis
  • Placebo vs Romosozumab · Cox proportional hazards · p = 0.012 · Hazard ratio (hr): 0.60 · 95% CI 0.40 to 0.90Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With a Major Osteoporotic Fracture Through Month 24

Major osteoporotic fractures included clinical vertebral fractures and fractures of the hip, forearm and humerus. Fractures associated with high trauma severity or pathologic fractures were excluded.

Time frame:
24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With a Major Osteoporotic Fracture Through Month 24
percentage of participantsPlacebo/DenosumabRomosozumab/Denosumab
Percentage of Participants With a Major Osteoporotic Fracture Through Month 243.11.9
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · Cox proportional hazards · p = 0.002 · Hazard ratio (hr): 0.62 · 95% CI 0.46 to 0.84Hazard ratio \< 1 favors romosozumab.
SecondaryPercentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12

A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 12
percentage of participantsPlaceboRomosozumab
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 120.30.03
Statistical analysis
  • Placebo vs Romosozumab · Regression, Logistic · p = 0.011 · Odds ratio (or): 0.11 · 95% CI 0.01 to 0.87Values \< 1 for odds ratio favor romosozumab.
SecondaryPercentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24

A new or worsening vertebral fracture was identified when there was a ≥ 1 grade increase from the previous grade in any vertebra from T4 to L4. A participant had multiple new or worsening vertebral fractures when there were ≥ 2 vertebrae from T4 to L4 with ≥ 1 grade increase from the previous grade. The multiple new or worsening vertebral fractures need not have occurred at the same visit.

Time frame:
24 Months
Reported as:
Number · percentage of participants
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 24
percentage of participantsPlacebo/DenosumabRomosozumab/Denosumab
Percentage of Participants With Multiple New or Worsening Vertebral Fractures Through Month 240.50.03
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · Regression, Logistic · p = < 0.001 · Odds ratio (or): 0.06 · 95% CI 0.01 to 0.44Values \< 1 for odds ratio favor romosozumab.
SecondaryPercent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 12
percent changePlaceboRomosozumab
Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 120.4 ± 0.113.1 ± 0.1
Statistical analysis
  • Placebo vs Romosozumab · ANCOVA · p = < 0.001 · Ls mean difference: 12.7 · 95% CI 12.4 to 12.9
SecondaryPercent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 24
percent changePlacebo/DenosumabRomosozumab/Denosumab
Percent Change From Baseline In Bone Mineral Density at the Lumbar Spine at Month 245.5 ± 0.116.6 ± 0.1
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · ANCOVA · p = < 0.001 · Ls mean difference: 11.1 · 95% CI 10.8 to 11.4
SecondaryPercent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 12
percent changePlaceboRomosozumab
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 120.3 ± 0.16.0 ± 0.1
Statistical analysis
  • Placebo vs Romosozumab · ANCOVA · p = < 0.001 · Ls mean difference: 5.8 · 95% CI 5.6 to 6.0
SecondaryPercent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 24
percent changePlacebo/DenosumabRomosozumab/Denosumab
Percent Change From Baseline in Bone Mineral Density of the Total Hip at Month 243.2 ± 0.18.5 ± 0.1
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · ANCOVA · p = < 0.001 · Ls mean difference: 5.3 · 95% CI 5.1 to 5.5
SecondaryPercent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and Month 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 12
percent changePlaceboRomosozumab
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 120.3 ± 0.15.5 ± 0.1
Statistical analysis
  • Placebo vs Romosozumab · ANCOVA · p = < 0.001 · Ls mean difference: 5.2 · 95% CI 4.9 to 5.4
SecondaryPercent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24

Bone mineral density (BMD) was measured by dual-energy x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.

Time frame:
Baseline and Month 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 24
percent changePlacebo/DenosumabRomosozumab/Denosumab
Percent Change From Baseline in Bone Mineral Density of the Femoral Neck at Month 242.3 ± 0.17.3 ± 0.1
Statistical analysis
  • Placebo/Denosumab vs Romosozumab/Denosumab · ANCOVA · p = < 0.001 · Ls mean difference: 4.9 · 95% CI 4.7 to 5.2

Adverse events

Collected over Double-blind treatment period: 12 months; Overall study: 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12-Month Double-blind Period: Placebo—314/3,576 (8.8%)2,059/3,576 (57.6%)
12-Month Double-blind Period: Romosozumab—344/3,581 (9.6%)2,019/3,581 (56.4%)
36-Month Study Period: Placebo/Denosumab—733/3,576 (20.5%)2,434/3,576 (68.1%)
36-Month Study Period: Romosozumab/Denosumab—728/3,581 (20.3%)2,463/3,581 (68.8%)
Most frequent serious events
Showing 10 of 745
Most frequent serious events
Event12-Month Double-blind Period: Placebo12-Month Double-blind Period: Romosozumab36-Month Study Period: Placebo/Denosumab36-Month Study Period: Romosozumab/Denosumab
PneumoniaInfections and infestations10/357619/358137/357644/3581
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders15/35766/358128/357622/3581
OsteoarthritisMusculoskeletal and connective tissue disorders15/35766/358127/357621/3581
Femur fractureInjury, poisoning and procedural complications7/35764/358119/35769/3581
Atrial fibrillationCardiac disorders4/35766/358118/357617/3581
Radius fractureInjury, poisoning and procedural complications5/35763/358117/357614/3581
Urinary tract infectionInfections and infestations7/35764/358114/357617/3581
Acute myocardial infarctionCardiac disorders4/35766/358110/357616/3581
HypertensionVascular disorders5/35768/358112/357615/3581
CataractEye disorders5/35764/358114/357613/3581
Most frequent other events
Showing 10 of 19
Most frequent other events
Event12-Month Double-blind Period: Placebo12-Month Double-blind Period: Romosozumab36-Month Study Period: Placebo/Denosumab36-Month Study Period: Romosozumab/Denosumab
ArthralgiaMusculoskeletal and connective tissue disorders434/3576468/3581663/3576668/3581
NasopharyngitisInfections and infestations439/3576460/3581622/3576651/3581
Back painMusculoskeletal and connective tissue disorders380/3576373/3581573/3576518/3581
FallInjury, poisoning and procedural complications319/3576255/3581539/3576484/3581
Pain in extremityMusculoskeletal and connective tissue disorders299/3576278/3581407/3576417/3581
HypertensionVascular disorders260/3576219/3581411/3576384/3581
OsteoarthritisMusculoskeletal and connective tissue disorders210/3576184/3581329/3576321/3581
HeadacheNervous system disorders206/3576235/3581270/3576293/3581
Urinary tract infectionInfections and infestations142/3576130/3581263/3576244/3581
Viral upper respiratory tract infectionInfections and infestations227/3576206/3581263/3576230/3581

Baseline characteristics

The full analysis set consisted of all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo/DenosumabRomosozumab/DenosumabTotal
Mean70.8 ± 6.970.9 ± 7.070.9 ± 7.0
Age, Customized
Age, Customized(Participants)Placebo/DenosumabRomosozumab/DenosumabTotal
< 65 years7577681525
≥ 65 years283428215655
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/DenosumabRomosozumab/DenosumabTotal
Female359135897180
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo/DenosumabRomosozumab/DenosumabTotal
Hispanic or Latino141614272843
Not Hispanic or Latino217521624337
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/DenosumabRomosozumab/DenosumabTotal
White205220634115
Asian441425866
Black or African American7477151
American Indian/Alaska Native6364127
Native Hawaiian/Other Pacific Islander101
Multiple5960119
Other9019001801
Prevalent Vertebral Fracture Strata per Randomization
Prevalent Vertebral Fracture Strata per Randomization(Participants)Placebo/DenosumabRomosozumab/DenosumabTotal
Yes205204409
No338633856771
Age Strata per Randomization
Age Strata per Randomization(Participants)Placebo/DenosumabRomosozumab/DenosumabTotal
< 75 years247124704941
≥ 75 years112011192239
08

Study locations

218 sites
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Laguna Hills, California 92653, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    Santa Maria, California 93454, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Lakewood, Colorado 80227, United States
  • Research Site
    Leesburg, Florida 34748, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Plantation, Florida 33324, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Gainesville, Georgia 30501, United States
  • Research Site
    New Orleans, Louisiana 70121, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Detroit, Michigan 48236, United States
  • Research Site
    Albuquerque, New Mexico 87106, United States
  • Research Site
    Asheville, North Carolina 28803, United States
  • Research Site
    Fargo, North Dakota 58104, United States
  • Research Site
    Cincinnati, Ohio 45236, United States
  • Research Site
    Mayfield, Ohio 44143, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Denton, Texas 76210-8625, United States
  • Research Site
    Richmond, Virginia 23294, United States
  • Research Site
    Madison, Wisconsin 53705, United States
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1012AAR, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1015ABO, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1128AAF, Argentina
  • Research Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1430CKE, Argentina
  • Research Site
    Mar del Plata, Buenos Aires B7600DHK, Argentina
  • Research Site
    Cordoba, Córdoba X5000BNB, Argentina
  • Research Site
    Buenos Aires, 1425, Argentina
  • Research Site
    Buenos Aires, C1425ACG, Argentina
  • Research Site
    Maroubra, New South Wales 2035, Australia
  • Research Site
    St Leonards, New South Wales 2065, Australia
  • Research Site
    Herston, Queensland 4029, Australia
  • Research Site
    Keswick, South Australia 5035, Australia
  • Research Site
    Footscray, Victoria 3011, Australia
  • Research Site
    Geelong, Victoria 3220, Australia
  • Research Site
    Heidelberg West, Victoria 3081, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Bruxelles, 1000, Belgium
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4020, Belgium
  • Research Site
    Lommel, 3920, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Curitiba, Paraná 80030-110, Brazil
  • Research Site
    Sao Paulo, São Paulo 04063-001, Brazil
  • Research Site
    São Paulo, 04266-010, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    São Paulo, 05437-010, Brazil
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E1, Canada
  • Research Site
    Hamilton, Ontario L8N 1Y2, Canada
  • Research Site
    Oakville, Ontario L6M 1M1, Canada
  • Research Site
    Lachine, Quebec H8S 2E4, Canada
  • Research Site
    Quebec, G1V 3M7, Canada
  • Research Site
    Medellin, Antioquia 050021, Colombia
  • Research Site
    Barranquilla, Atlántico 08001000, Colombia
  • Research Site
    Bogota, Cundinamarca 11001000, Colombia
  • Research Site
    Bogota, Cundinamarca 110221, Colombia
  • Research Site
    Bogota, Cundinamarca 1, Colombia
  • Research Site
    Bogota, Cundinamarca, Colombia
  • Research Site
    Bogota, 11001000, Colombia
  • Research Site
    Brno, 602 00, Czechia
  • Research Site
    Ceske Budejovice, 370 87, Czechia
  • Research Site
    Havlickuv Brod, 580 22, Czechia
  • Research Site
    Klatovy, 339 38, Czechia
  • Research Site
    Ostrava-Trebovice, 722 00, Czechia
  • Research Site
    Pardubice, 530 02, Czechia
  • Research Site
    Plzen, 305 99, Czechia
  • Research Site
    Praha 11 - Chodov, 148 00, Czechia
  • Research Site
    Praha 2, 128 50, Czechia
  • Research Site
    Praha 3, 130 00, Czechia
  • Research Site
    Uherske Hradiste, 686 01, Czechia
  • Research Site
    Zlin, 760 01, Czechia
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Glostrup, 2600, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    Odense, 5000, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Århus C, 8000, Denmark
  • Research Site
    Santo Domingo, Distrito Nacional 10124, Dominican Republic
  • Research Site
    Santo Domingo, Distrito Nacional 10514, Dominican Republic
  • Research Site
    Santo Domingo, 10605, Dominican Republic
  • Research Site
    Pärnu, 80013, Estonia
  • Research Site
    Tallinn, 10128, Estonia
  • Research Site
    Tartu, 50410, Estonia
  • Research Site
    Berlin (Hellersdorf), 12627, Germany
  • Research Site
    Berlin, 12200, Germany
  • Research Site
    Bochum, 44787, Germany
  • Research Site
    Dresden, 01067, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Frankfurt am Main, 60313, Germany
  • Research Site
    Frankfurt am Main, 60528, Germany
  • Research Site
    Görlitz, 02826, Germany
  • Research Site
    Hamburg, 20354, Germany

Showing the first 100 of 218 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18. PubMed 27641143 ↗
  • Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K, Matsumoto T, Milmont CE, Libanati C, Grauer A. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. J Bone Miner Res. 2018 Jul;33(7):1219-1226. doi: 10.1002/jbmr.3427. Epub 2018 May 17. PubMed 29573473 ↗
  • Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP, Libanati C, Boyce RW, Wang A, Grauer A. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. J Bone Miner Res. 2019 Sep;34(9):1597-1608. doi: 10.1002/jbmr.3735. Epub 2019 Jun 24. PubMed 31233639 ↗
  • Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C, Milmont CE, Meisner PD, Libanati C, Grauer A. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. J Bone Miner Res. 2018 Aug;33(8):1407-1416. doi: 10.1002/jbmr.3439. Epub 2018 May 11. PubMed 29750828 ↗
  • Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. J Bone Miner Res. 2019 Mar;34(3):419-428. doi: 10.1002/jbmr.3622. Epub 2018 Dec 3. PubMed 30508316 ↗
  • Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos. 2019 Jun 5;14(1):59. doi: 10.1007/s11657-019-0608-z. PubMed 31168657 ↗
  • Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C, Shimauchi J. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab. 2021 Mar;39(2):278-288. doi: 10.1007/s00774-020-01147-5. Epub 2020 Oct 15. PubMed 33057807 ↗
  • McCloskey EV, Johansson H, Harvey NC, Lorentzon M, Shi Y, Kanis JA. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int. 2021 Aug;32(8):1601-1608. doi: 10.1007/s00198-020-05815-0. Epub 2021 Feb 3. PubMed 33537844 ↗
  • Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, Betah D, Libanati C, Chavassieux P. Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial. J Bone Miner Res. 2022 Jan;37(1):36-40. doi: 10.1002/jbmr.4457. Epub 2021 Nov 19. PubMed 34633116 ↗
  • Miller PD, Adachi JD, Albergaria BH, Cheung AM, Chines AA, Gielen E, Langdahl BL, Miyauchi A, Oates M, Reid IR, Santiago NR, Vanderkelen M, Wang Z, Yu Z. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease. J Bone Miner Res. 2022 Aug;37(8):1437-1445. doi: 10.1002/jbmr.4563. Epub 2022 May 20. PubMed 35466448 ↗
  • Takada J, Dinavahi R, Miyauchi A, Hamaya E, Hirama T, Libanati C, Nakamura Y, Milmont CE, Grauer A. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. J Bone Miner Metab. 2020 May;38(3):310-315. doi: 10.1007/s00774-019-01057-1. Epub 2019 Nov 9. Erratum In: J Bone Miner Metab. 2020 Jul;38(4):605. doi: 10.1007/s00774-020-01099-w. PubMed 31707465 ↗
  • Miyauchi A, Hamaya E, Nishi K, Tolman C, Shimauchi J. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab. 2022 Jul;40(4):677-687. doi: 10.1007/s00774-022-01332-8. Epub 2022 May 31. PubMed 35639174 ↗
  • Eriksen EF, Boyce RW, Shi Y, Brown JP, Betah D, Libanati C, Oates M, Chapurlat R, Chavassieux P. Reconstruction of remodeling units reveals positive effects after 2 and 12 months of romosozumab treatment. J Bone Miner Res. 2024 Jul 23;39(6):729-736. doi: 10.1093/jbmr/zjae055. PubMed 38640512 ↗
  • Lane NE, Betah D, Deignan C, Oates M, Wang Z, Timoshanko J, Khan AA, Binkley N. Effect of Romosozumab Treatment in Postmenopausal Women With Osteoporosis and Knee Osteoarthritis: Results From a Substudy of a Phase 3 Clinical Trial. ACR Open Rheumatol. 2024 Jan;6(1):43-51. doi: 10.1002/acr2.11619. Epub 2023 Nov 20. PubMed 37985218 ↗
  • McClung MR, Betah D, Deignan C, Shi Y, Timoshanko J, Cosman F. Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk. Endocr Pract. 2023 Sep;29(9):716-722. doi: 10.1016/j.eprac.2023.06.011. Epub 2023 Jul 4. PubMed 37406858 ↗
  • Cosman F, Oates M, Betah D, Timoshanko J, Wang Z, Ferrari S, McClung MR. Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. J Bone Miner Res. 2024 Sep 2;39(9):1268-1277. doi: 10.1093/jbmr/zjae116. PubMed 39041711 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Dec 2015, 44 months.

Results were first posted in Nov 2018, 2 years 10 months after primary completion. A results delay was requested in Mar 2016.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 44 months is above that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2012
First posted
Apr 12, 2012
StartActual
Mar 15, 2012
Primary completionActual
Dec 14, 2015
CompletionActual
Dec 28, 2016
Results delay requested
Mar 7, 2016
Results first posted
Nov 8, 2018
Last update
Aug 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01575834
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 12, 2012
Start date
Mar 15, 2012
Primary completion
Dec 14, 2015
Completion
Dec 28, 2016
Results posted
Nov 8, 2018
Last update
Aug 28, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romosozumab

Start the discussion